

# Zahir Amoura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7320714/publications.pdf>

Version: 2024-02-01

347  
papers

29,879  
citations

3334

91  
h-index

6471

157  
g-index

370  
all docs

370  
docs citations

370  
times ranked

26387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Libman-â€“Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases. <i>Rheumatology</i> , 2023, 62, 707-715.	1.9	4
2	Response to: â€“Implications of SARS-CoV-2 infection for patients with rheumatic diseaseâ€™ by Lin<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e153-e153.	0.9	2
3	Response to: â€“Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial"â€™ by Mousavi and Taherifard. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e47-e47.	0.9	0
4	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 575-583.	0.9	61
5	Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation. <i>Frontiers in Immunology</i> , 2022, 13, 790334.	4.8	10
6	The consequences of COVID-19 pandemic on patients with monoclonal gammopathyâ€“associated systemic capillary leak syndrome (Clarkson disease). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 626-629.	3.8	6
7	Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study). <i>Rheumatology</i> , 2022, 61, 4355-4363.	1.9	14
8	Anticancer Drug-Induced Capillary Leak Syndrome. <i>Kidney International Reports</i> , 2022, 7, 945-953.	0.8	14
9	Prevalence and factors associated with long-term remission in cutaneous lupus: A longitudinal cohort study of 141 cases. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 323-332.	1.2	4
10	Soluble CD163 and incident cardiovascular events in patients with systemic lupus erythematosus: An observational cohort study. <i>Journal of Internal Medicine</i> , 2022, 292, 536-539.	6.0	2
11	Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1420-1427.	0.9	24
12	Erdheim-Chester disease: An orbital MRI study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19085-e19085.	1.6	0
13	Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7059-7059.	1.6	0
14	Psychiatric autoimmune conditions in children and adolescents: Is catatonia a severity marker?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110028.	4.8	11
15	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	1.4	30
16	IgA dominates the early neutralizing antibody response to SARS-CoV-2. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	840
17	Cutaneous Kikuchi disease-like inflammatory pattern without lymph node involvement is associated with systemic disease and severe features in lupus erythematosus: A case-control study. <i>Lupus</i> , 2021, 30, 473-477.	1.6	1
18	New insights on IgA vasculitis with underlying solid tumor: a nationwide French study of 30 patients. <i>Clinical Rheumatology</i> , 2021, 40, 1933-1940.	2.2	10

#	ARTICLE	IF	CITATIONS
19	Highly sensitive serum cardiac troponin T and cardiovascular events in patients with systemic lupus erythematosus (TROPOPLUS study). <i>Rheumatology</i> , 2021, 60, 1210-1215.	1.9	6
20	Impact of aging on phenotype and prognosis in IgA vasculitis. <i>Rheumatology</i> , 2021, 60, 4245-4251.	1.9	9
21	Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration. <i>Kidney International Reports</i> , 2021, 6, 526-528.	0.8	8
22	Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). <i>Arthritis Research and Therapy</i> , 2021, 23, 70.	3.5	12
23	Sustained high expression of multiple APOBEC3 cytidine deaminases in systemic lupus erythematosus. <i>Scientific Reports</i> , 2021, 11, 7893.	3.3	8
24	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , 2021, 23, 1433-1446.	1.2	33
25	Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2021, 12, 633658.	4.8	10
26	Evolution of Nutritional Status after Early Nutritional Management in COVID-19 Hospitalized Patients. <i>Nutrients</i> , 2021, 13, 2276.	4.1	21
27	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. <i>Autoimmunity Reviews</i> , 2021, 20, 102874.	5.8	2
28	Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease. <i>Pancreas</i> , 2021, 50, e6-e8.	1.1	2
29	Clarkson's Disease Episode or Secondary Systemic Capillary Leak-Syndrome. <i>Chest</i> , 2021, 159, 441.	0.8	5
30	MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis. <i>Leukemia</i> , 2021, , .	7.2	3
31	Lower Rate of Daily Smokers With Symptomatic COVID-19: A Monocentric Self-Report of Smoking Habit Study. <i>Frontiers in Medicine</i> , 2021, 8, 668995.	2.6	23
32	Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1721-1729.	0.7	7
33	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	3.5	34
34	Handling shock in idiopathic systemic capillary leak syndrome (Clarkson's disease): less is more comment. <i>Internal and Emergency Medicine</i> , 2020, 15, 347-348.	2.0	3
35	Lung Involvement in Destombes-Rosai-Dorfman Disease. <i>Chest</i> , 2020, 157, 323-333.	0.8	17
36	Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 339-346.	0.9	93

#	ARTICLE	IF	CITATIONS
37	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	2.0	10
38	Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence. <i>Arthritis Research and Therapy</i> , 2020, 22, 223.	3.5	18
39	Response to: Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease™ by Campochiaro et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2019-216755.	0.9	1
40	Central nervous system involvement in Erdheim-Chester disease. <i>Neurology</i> , 2020, 95, e2746-e2754.	1.1	22
41	Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. <i>New England Journal of Medicine</i> , 2020, 383, 1117-1128.	27.0	506
42	Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of the GOODLUPUS Study. <i>Frontiers in Immunology</i> , 2020, 11, 597863.	4.8	3
43	The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. <i>Cancers</i> , 2020, 12, 3240.	3.7	5
44	Immune phenotyping of Erdheim-Chester disease through mass cytometry highlights decreased proportion of non-classical monocytes and increased proportion of Th17 cells. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1522-1524.	0.9	6
45	SARS-CoV-2 Induces Acute and Refractory Relapse of Systemic Capillary Leak Syndrome (Clarkson's) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 107	1.5	24
46	Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. <i>Rheumatology</i> , 2020, 59, 3050-3057.	1.9	23
47	Disease-specific quality of life following a flare in systemic lupus erythematosus: an item response theory analysis of the French EQUAL cohort. <i>Rheumatology</i> , 2020, 59, 1398-1406.	1.9	12
48	Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations. <i>Lupus Science and Medicine</i> , 2020, 7, e000399.	2.7	11
49	Erdheim-Chester disease. <i>Blood</i> , 2020, 135, 1311-1318.	1.4	99
50	A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications. , 2020, 343, 33-39.		193
51	Long-bones involvement in generalized crystal-storing histiocytosis. <i>Joint Bone Spine</i> , 2019, 86, 652-653.	1.6	3
52	Atteintes ostéoarticulaires au cours des histiocytoses. <i>Revue Du Rhumatisme Monographies</i> , 2019, 86, 120-125.	0.0	0
53	Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 107 Oncology Reports, 2019, 21, 62.	4.0	48
54	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.9	664

#	ARTICLE	IF	CITATIONS
55	Renal toxicities associated with pembrolizumab. CKJ: Clinical Kidney Journal, 2019, 12, 81-88.	2.9	101
56	Expanding the spectrum of HIV-associated myopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1296-1298.	1.9	7
57	IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000787.	3.8	21
58	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	3.8	19
59	Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. Haematologica, 2019, 104, e502-e505.	3.5	15
60	Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. Journal of Neurology, 2019, 266, 1073-1078.	3.6	18
61	Mixed connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000783.	3.8	30
62	Management of difficult infections in SLE. , 2019, , .		0
63	SAT0188â€¦WHOLE BLOOD VERSUS SERUM HYDROXYCHLOROQUINE LEVELS FOR DRUG MONITORING OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS OF A PHARMACOLOGICAL STUDY. , 2019, , .		0
64	Development and Validation of a Fast Ultra-High Performance Liquid Chromatographyâ€“Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients With Lupus. Therapeutic Drug Monitoring, 2019, 41, 476-482.	2.0	14
65	Erdheim-Chester Disease: a Concise Review. Current Rheumatology Reports, 2019, 21, 66.	4.7	38
66	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. Journal of Allergy and Clinical Immunology, 2019, 143, 1575-1585.e4.	2.9	86
67	Neurosarcoidosis. , 2019, , 115-125.		0
68	Systemic lupus erythematosus: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000793.	3.8	66
69	Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica, 2019, 104, e97-e99.	3.5	27
70	High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment. Blood, 2019, 134, 2324-2324.	1.4	2
71	Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe episodes. Journal of Allergy and Clinical Immunology, 2018, 141, 1539-1540.	2.9	11
72	Cerebrovascular events in Takayasu arteritis: a multicenter case-controlled study. Journal of Neurology, 2018, 265, 757-763.	3.6	31

#	ARTICLE	IF	CITATIONS
73	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. <i>American Journal of Hematology</i> , 2018, 93, E114-E117.	4.1	94
74	Efficacy of infliximab in the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1387-1390.	0.9	22
75	Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. <i>American Journal of Hematology</i> , 2018, 93, 424-429.	4.1	56
76	Microbial ecology perturbation in human IgA deficiency. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	206
77	Symptomatic muscular sarcoidosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e452.	6.0	27
78	Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212705.	0.9	38
79	Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease. <i>British Journal of Haematology</i> , 2018, 180, 150-153.	2.5	55
80	Aortic involvement in relapsing polychondritis. <i>Joint Bone Spine</i> , 2018, 85, 345-351.	1.6	14
81	Cerebrovascular events are associated with lower survival in giant cell arteritis: A case-controlled multicenter study. <i>Joint Bone Spine</i> , 2018, 85, 383-385.	1.6	11
82	A causality algorithm to guide diagnosis and treatment of catatonia due to autoimmune conditions in children and adolescents. <i>Schizophrenia Research</i> , 2018, 200, 68-76.	2.0	19
83	Catastrophic antiphospholipid syndrome (CAPS)-induced ischemic pancreatic ducts injury mimicking intraductal papillary mucinous neoplasm (IPMN). <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 565-568.	3.4	4
84	Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus. <i>Chest</i> , 2018, 153, 143-151.	0.8	68
85	Characteristics, outcome and treatments with cranial pachymeningitis. <i>Medicine (United States)</i> , 2018, 97, e11413.	1.0	23
86	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	3.8	38
87	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018, 17, 1153-1168.	5.8	62
88	Detection in whole blood of autoantibodies for the diagnosis of connective tissue diseases in near patient testing condition. <i>PLoS ONE</i> , 2018, 13, e0202736.	2.5	12
89	Hypoalphalipoproteinemia and BRAF <sup>V600E</sup> Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1913-1925.	2.4	15
90	Lupus and vaccinations. <i>Current Opinion in Rheumatology</i> , 2018, 30, 465-470.	4.3	14

#	ARTICLE	IF	CITATIONS
91	PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease. <i>Blood</i> , 2018, 132, 4380-4380.	1.4	0
92	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw382.	0.7	67
93	Catatonia and Autoimmune Conditions in Children and Adolescents: Should We Consider a Therapeutic Challenge?. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017, 27, 167-176.	1.3	15
94	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology</i> , The, 2017, 18, e113-e125.	10.7	154
95	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 510-519.	9.1	366
96	Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 288-294.	3.4	81
97	Long-term outcomes of refractory neurosarcoidosis treated with infliximab. <i>Journal of Neurology</i> , 2017, 264, 891-897.	3.6	90
98	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
99	Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. <i>Autoimmunity Reviews</i> , 2017, 16, 743-749.	5.8	101
100	The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission. <i>Critical Care Medicine</i> , 2017, 45, 1216-1223.	0.9	56
101	Successful outcome of proliferative lupus nephritis during pregnancy: Toward a modern paradigm of lupus pregnancy?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 214, 201-203.	1.1	0
102	Subcutaneous immunoglobulins for the treatment of a patient with antisynthetase syndrome and secondary chronic immunodeficiency after anti-CD20 treatment: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 58.	0.8	4
103	Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. <i>Journal of Neurology</i> , 2017, 264, 1218-1226.	3.6	23
104	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 130, 176-180.	1.4	98
105	Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome. <i>American Journal of Medicine</i> , 2017, 130, 1219.e19-1219.e27.	1.5	53
106	Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. <i>Arthritis and Rheumatology</i> , 2017, 69, 1862-1870.	5.6	117
107	Neurodegeneration in histiocytoses might start in utero. <i>Lancet Neurology</i> , The, 2017, 16, 953-954.	10.2	2
108	Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon- $\beta$ monoclonal antibody, in SLE subjects without or with lupus nephritis. <i>Lupus Science and Medicine</i> , 2017, 4, e000226.	2.7	49

#	ARTICLE	IF	CITATIONS
109	Cerebral pseudo-tumoral neuro-Behcet: Histological demonstration of an inflammatory and vascular disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 161, 48-50.	1.4	10
110	High prevalence of myeloid neoplasms in adults with non- $\alpha$ -Langerhans cell histiocytosis. <i>Blood</i> , 2017, 130, 1007-1013.	1.4	98
111	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017, 130, 1377-1380.	1.4	146
112	Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients. <i>Journal of Rheumatology</i> , 2017, 44, 24-32.	2.0	80
113	Spinal Koebner phenomenon: Medullar sarcoidosis facing a discal hernia. <i>Joint Bone Spine</i> , 2017, 84, 497-498.	1.6	7
114	Pulmonary hyalinizing granuloma: a multicenter study of 5 new cases and review of the 135 cases of the literature. <i>Immunologic Research</i> , 2017, 65, 375-385.	2.9	30
115	Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells. <i>Oncotarget</i> , 2017, 8, 104733-104744.	1.8	20
116	Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy). <i>Medicine (United States)</i> , 2016, 95, e3632.	1.0	71
117	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1009-1015.	0.9	112
118	Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. <i>Blood</i> , 2016, 127, 1509-1512.	1.4	49
119	Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 316-333.	3.3	79
120	Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. <i>Autoimmunity Reviews</i> , 2016, 15, 994-1000.	5.8	48
121	Treatment of neurosarcoidosis. <i>Neurology</i> , 2016, 87, 2517-2521.	1.1	82
122	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. <i>Medicine (United States)</i> , 2016, 95, e3748.	1.0	64
123	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2016, 5, e1181244.	4.6	14
124	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 513-520.	1.2	64
125	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. <i>Rheumatology</i> , 2016, 55, 291-300.	1.9	170
126	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372



#	ARTICLE	IF	CITATIONS
127	Thrombopoietin-Receptor Agonist in Systemic Lupus Erythematosus Associated Immune Thrombocytopenia: Results of the 16 Patients from the French Cohort. <i>Blood</i> , 2016, 128, 2542-2542.	1.4	3
128	Can Rituximab be Useful for Treating SLE-Associated Immune Cytopenias ? Results from a Retrospective Multicentre Study on 62 Patients. <i>Blood</i> , 2016, 128, 870-870.	1.4	1
129	Frequent Clinical Overlap of Histiocytic Neoplasms and WHO-Classified Myeloid Malignancies Leads to Functional Insights into the Cell-of-Origin of Histiocytoses. <i>Blood</i> , 2016, 128, 951-951.	1.4	3
130	Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7069-7069.	1.6	0
131	Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19074-e19074.	1.6	0
132	Determinants of Hydroxychloroquine Blood Concentration Variations in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2176-2184.	5.6	118
133	mTOR: a new target in Erdheim-Chester disease?. <i>Blood</i> , 2015, 126, 1151-1152.	1.4	3
134	Spontaneous remission of fully symptomatic visceral leishmaniasis. <i>BMC Infectious Diseases</i> , 2015, 15, 445.	2.9	4
135	Ultraviolet light converts propranolol, a nonselective $\beta$ -blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. <i>European Journal of Immunology</i> , 2015, 45, 3174-3187.	2.9	36
136	Thrombophilia Associated with Anti-DFS70 Autoantibodies. <i>PLoS ONE</i> , 2015, 10, e0138671.	2.5	17
137	Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0143689.	2.5	37
138	Blockade of Interferon $\gamma$ Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2015, 67, 2713-2722.	5.6	60
139	In Antisynthetase Syndrome, ACPA Are Associated With Severe and Erosive Arthritis. <i>Medicine (United States)</i> 10.784314. <a href="#">rgBT /O</a>	1.0	49
140	Reversible Severe Eosinophilic Endomyocardial Fibrosis During Pregnancy. <i>Medicine (United States)</i> , 2015, 94, e1307.	1.0	1
141	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With <i>BRAF</i> <sup>V600E</sup> -Mutated Erdheim-Chester Disease. <i>Journal of Clinical Oncology</i> , 2015, 33, 411-418.	1.6	238
142	Influence of smoking on the efficacy of antimalarials in cutaneous lupus: A meta-analysis of the literature. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 634-639.	1.2	87
143	The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1033-1042.	3.0	38
144	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e29-e30.	1.2	22

#	ARTICLE	IF	CITATIONS
145	Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 <sup>high</sup> regulatory T cells in humans. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7225-7230.	7.1	164
146	Targeting Interferons in Systemic Lupus Erythematosus: Current and Future Prospects. Drugs, 2015, 75, 835-846.	10.9	58
147	Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmunity Reviews, 2015, 14, 1154-1160.	5.8	121
148	Efficacy of Biological-Targeted Treatments in Takayasu Arteritis. Circulation, 2015, 132, 1693-1700.	1.6	157
149	Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmunity Reviews, 2015, 14, 192-200.	5.8	118
150	Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology, 2015, 54, 940-949.	1.9	58
151	Pulmonary Involvement in Takayasu Arteritis and Behçet Disease. , 2015, , 177-190.		0
152	Chronic Malaria Revealed by a New Fluorescence Pattern on the Antinuclear Autoantibodies Test. PLoS ONE, 2014, 9, e88548.	2.5	13
153	Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology, 2014, 83, 1294-1296.	1.1	29
154	Epidemiology of Primary Sjögren's Syndrome in a French Multiracial/Multiethnic Area. Arthritis Care and Research, 2014, 66, 454-463.	3.4	107
155	Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Science and Medicine, 2014, 1, e000027.	2.7	54
156	Kikuchi-Fujimoto Disease. Medicine (United States), 2014, 93, 372-382.	1.0	160
157	Central nervous system angiitis: a series of 31 patients. Clinical Rheumatology, 2014, 33, 105-110.	2.2	21
158	Erdheim-Chester Disease. Current Rheumatology Reports, 2014, 16, 412.	4.7	110
159	Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. Autoimmunity Reviews, 2014, 13, 730-735.	5.8	79
160	Successful treatment of combined proliferative and membranous lupus nephritis using a full corticosteroid-free regimen. Annals of the Rheumatic Diseases, 2014, 73, 474-475.	0.9	12
161	Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis. Autoimmunity Reviews, 2014, 13, 281-291.	5.8	166
162	Type B Insulin-resistance syndrome: a cause of reversible autoimmune hypoglycaemia. Lancet, The, 2014, 384, 1548.	13.7	19

#	ARTICLE	IF	CITATIONS
163	Annual direct medical cost of active systemic lupus erythematosus in five European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 154-160.	0.9	68
164	Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1209-1215.	2.2	41
165	Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. <i>Autoimmunity Reviews</i> , 2014, 13, 1082-1089.	5.8	106
166	Survival analysis versus event count. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e37-e37.	0.9	1
167	Mortality Associated With Systemic Lupus Erythematosus in France Assessed by Multiple Cause of Death Analysis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2503-2511.	5.6	152
168	Pathogenesis of relapsing polychondritis: A 2013 update. <i>Autoimmunity Reviews</i> , 2014, 13, 90-95.	5.8	110
169	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019.	1.4	197
170	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. <i>Blood</i> , 2014, 124, 1119-1126.	1.4	208
171	Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study. <i>Blood</i> , 2014, 124, 3254-3254.	1.4	0
172	Lupus enteritis: from clinical findings to therapeutic management. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 67.	2.7	116
173	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2013, 149, 935.	4.1	91
174	Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. <i>Rheumatology</i> , 2013, 52, 1635-1641.	1.9	56
175	Small vessel involvement in Takayasu's arteritis. <i>Autoimmunity Reviews</i> , 2013, 12, 355-362.	5.8	41
176	Anakinra in Adult Onset Still's Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy. <i>Arthritis Care and Research</i> , 2013, 65, 822-826.	3.4	103
177	HTLV-1-associated inflammatory myopathies: Low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. <i>Journal of Clinical Virology</i> , 2013, 57, 70-76.	3.1	17
178	Erdheim-Chester Disease. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 299-311.	1.9	91
179	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. <i>European Respiratory Journal</i> , 2013, 42, 1271-1282.	6.7	108
180	Study of Anti-Müllerian Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3785-3792.	3.6	51

#	ARTICLE	IF	CITATIONS
181	Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1786-1792.	0.9	160
182	Traitement du lupus Érythémateux systémique. , 2013, , 73-90.		2
183	Primary Adrenal Insufficiency Due to Bilateral Adrenal Hemorrhage-Adrenal Infarction in the Antiphospholipid Syndrome: Long-Term Outcome of 16 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3179-3189.	3.6	72
184	Clinical Phenotypes of Patients with Anti-DFS70/LEDGF Antibodies in a Routine ANA Referral Cohort. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	65
185	Acute Renal Infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 392-398.	4.5	135
186	Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis. <i>European Respiratory Journal</i> , 2013, 41, 115-122.	6.7	93
187	<i>BRAF</i> Mutations in Erdheim-Chester Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 398-398.	1.6	65
188	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. <i>Blood</i> , 2013, 121, 1495-1500.	1.4	479
189	Sjögren Syndrome-Associated Small Fiber Neuropathy. <i>Medicine (United States)</i> , 2013, 92, e10-e18.	1.0	51
190	LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2012, 51, 1906-1915.	1.9	43
191	Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. <i>Rheumatology</i> , 2012, 51, 557-561.	1.9	131
192	Lupus Anticoagulant-Hypoprothrombinemia Syndrome. <i>Medicine (United States)</i> , 2012, 91, 251-260.	1.0	85
193	Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1227-1234.	0.9	90
194	Whole-body MRI in Erdheim-Chester disease. <i>Rheumatology</i> , 2012, 51, 948-950.	1.9	9
195	Pseudotumoural presentation of neuro-Behcet's disease: case series and review of literature. <i>Rheumatology</i> , 2012, 51, 1216-1225.	1.9	45
196	Erdheim-Chester disease. <i>Current Opinion in Rheumatology</i> , 2012, 24, 53-59.	4.3	156
197	Inflammatory Myopathies With Anti-Ku Antibodies. <i>Medicine (United States)</i> , 2012, 91, 95-102.	1.0	90
198	Long-Term Outcome of Arterial Lesions in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 18-24.	1.0	175

#	ARTICLE	IF	CITATIONS
199	Spectrum of Cardiac Lesions in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 25-34.	1.0	199
200	A 75-Year-Old Woman Admitted to the ICU With Respiratory Failure. <i>Chest</i> , 2012, 142, 1063-1067.	0.8	2
201	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. <i>Blood</i> , 2012, 120, 2700-2703.	1.4	589
202	Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome?. <i>Rheumatology International</i> , 2012, 32, 3285-3290.	3.0	51
203	Independent Replication and Metaanalysis of Association Studies Establish TNFSF4 as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 997-1003.	2.0	35
204	The Relapsing Polychondritis Disease Activity Index: Development of a disease activity score for relapsing polychondritis. <i>Autoimmunity Reviews</i> , 2012, 12, 204-209.	5.8	71
205	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. <i>Autoimmunity Reviews</i> , 2012, 12, 210-217.	5.8	233
206	Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use. <i>Journal of Rheumatology</i> , 2012, 39, 1835-1839.	2.0	48
207	Ocular Whipple's Disease: Therapeutic Strategy and Long-Term Follow-Up. <i>Ophthalmology</i> , 2012, 119, 1465-1469.	5.2	53
208	Medical and developmental risk factors of catatonia in children and adolescents: A prospective case-control study. <i>Schizophrenia Research</i> , 2012, 137, 151-158.	2.0	72
209	Late-Onset Systemic Lupus Erythematosus. <i>Drugs and Aging</i> , 2012, 29, 181-189.	2.7	78
210	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
211	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2746-2752.	6.7	63
212	Predictive value and clinical interest of the antiphospholipid score: Comment on the article by Otomo et al. <i>Arthritis and Rheumatism</i> , 2012, 64, 2806-2807.	6.7	0
213	Anti TNF- $\alpha$ in refractory Takayasu's arteritis: Cases series and review of the literature. <i>Autoimmunity Reviews</i> , 2012, 11, 678-684.	5.8	132
214	Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon- $\alpha$ . <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 907-913.	3.4	83
215	Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study. <i>PLoS ONE</i> , 2012, 7, e42418.	2.5	19
216	F-18 FDG-PET/CT in aseptic abscesses with recurrent febrile abdominal pain. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 577-582.	1.5	11

#	ARTICLE	IF	CITATIONS
217	Interferon-Alpha in Cardiac Erdheim-Chester Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2695.	2.8	5
218	QuantIFERON-TB Gold Cut-off Value: Implications for the Management of Tuberculosis-Related Ocular Inflammation. <i>American Journal of Ophthalmology</i> , 2011, 152, 433-440.e1.	3.3	92
219	Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. <i>Contraception</i> , 2011, 83, 229-237.	1.5	57
220	Impaired carbon monoxide diffusing capacity as a marker of limited systemic sclerosis. <i>European Journal of Internal Medicine</i> , 2011, 22, e80-e86.	2.2	5
221	Antimalarials and SLE. , 2011, , 1061-1081.		2
222	Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. <i>Blood</i> , 2011, 117, 2783-2790.	1.4	144
223	CNS involvement and treatment with interferon- $\beta$ are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. <i>Blood</i> , 2011, 117, 2778-2782.	1.4	331
224	The Systemic Capillary Leak Syndrome. <i>Annals of Internal Medicine</i> , 2011, 155, 335.	3.9	0
225	The Systemic Capillary Leak Syndrome: A Case Series of 28 Patients From a European Registry. <i>Annals of Internal Medicine</i> , 2011, 154, 464.	3.9	130
226	The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2011, 10, 674-678.	5.8	30
227	Human FoxP3+ regulatory T cells in systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2011, 10, 744-755.	5.8	298
228	Pathogenesis of Takayasu's arteritis: A 2011 update. <i>Autoimmunity Reviews</i> , 2011, 11, 61-67.	5.8	223
229	Mononeuropathy multiplex associated with acute parvovirus B19 infection: characteristics, treatment and outcome. <i>Journal of Neurology</i> , 2011, 258, 1321-1326.	3.6	20
230	Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2011, 5, 15.	2.5	52
231	Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. <i>Movement Disorders</i> , 2011, 26, 2422-2427.	3.9	61
232	Multiparameter grouping delineates heterogeneous populations of human IL-17 and/or IL-22 T $\alpha$ 1 cell producers that share antigen specificities with other T $\alpha$ 1 cell subsets. <i>European Journal of Immunology</i> , 2011, 41, 2596-2605.	2.9	19
233	Cluster analysis of arterial involvement in Takayasu arteritis reveals symmetric extension of the lesions in paired arterial beds. <i>Arthritis and Rheumatism</i> , 2011, 63, 1136-1140.	6.7	39
234	Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon- $\beta$ production in patients with active disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 1698-1706.	6.7	116

#	ARTICLE	IF	CITATIONS
235	Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. <i>Arthritis and Rheumatism</i> , 2011, 63, 1961-1971.	6.7	168
236	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2091-2096.	6.7	45
237	Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3502-3511.	6.7	42
238	Ultrasound, Elastography, and Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Riedel's Thyroiditis: Report of Two Cases. <i>Thyroid</i> , 2011, 21, 799-804.	4.5	35
239	A New Presentation of Neonatal Lupus: 5 Cases of Isolated Mild Endocardial Fibroelastosis Associated with Maternal Anti-SSA/Ro and Anti-SSB/La Antibodies. <i>Journal of Rheumatology</i> , 2011, 38, 378-386.	2.0	51
240	IFN- $\lambda$ and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18995-19000.	7.1	52
241	Active immunisation of human interferon $\lambda$ transgenic mice with a human interferon $\lambda$ Kinoid induces antibodies that neutralise interferon $\lambda$ in sera from patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1138-1143.	0.9	41
242	Preventing Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 996.	7.4	2
243	162 Active Anti-IFN $\lambda$ Immunotherapy Applied to Chronic Viral and Autoimmune Diseases. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 68.	2.1	11
244	Association Study of <i>ITGAM</i> , <i>ITGAX</i> , and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	2.0	22
245	Peripheral Neuropathies Associated With Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2011, 90, 133-138.	1.0	94
246	Independent replication establishes the CD247 gene as a genetic systemic sclerosis susceptibility factor. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1695-1696.	0.9	46
247	Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. <i>Rheumatology</i> , 2011, 50, 2283-2289.	1.9	56
248	Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjogren's syndrome. <i>Rheumatology</i> , 2011, 50, 1175-1176.	1.9	16
249	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. <i>PLoS Pathogens</i> , 2011, 7, e1002328.	4.7	111
250	Takayasu Arteritis in France. <i>Medicine (United States)</i> , 2010, 89, 1-17.	1.0	138
251	Spinal Cord Sarcoidosis. <i>Medicine (United States)</i> , 2010, 89, 133-140.	1.0	73
252	Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. <i>Blood</i> , 2010, 116, 4523-4531.	1.4	126

#	ARTICLE	IF	CITATIONS
253	Erdheim-Chester disease: CT findings of thoracic involvement. <i>European Radiology</i> , 2010, 20, 2579-2587.	4.5	74
254	Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: Clinical and immunological features: A propos of 40 new cases and review of the literature. <i>Autoimmunity Reviews</i> , 2010, 9, 652-656.	5.8	21
255	Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. <i>Joint Bone Spine</i> , 2010, 77, 4-5.	1.6	34
256	The presence of atherosclerotic plaques in patients with Takayasu arteritis: Comment on the article by Keenan et al. <i>Arthritis and Rheumatism</i> , 2010, 62, 1558-1559.	6.7	2
257	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. <i>Arthritis and Rheumatism</i> , 2010, 62, 2047-2054.	6.7	85
258	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. <i>Arthritis and Rheumatism</i> , 2010, 62, 2458-2466.	6.7	352
259	Pulmonary involvement in Erdheim-Chester disease: A single-center study of thirty-four patients and a review of the literature. <i>Arthritis and Rheumatism</i> , 2010, 62, 3504-3512.	6.7	114
260	Successful Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock Due to the Catastrophic Antiphospholipid Syndrome. <i>Annals of Internal Medicine</i> , 2010, 153, 487.	3.9	8
261	Cerebral, Facial, and Orbital Involvement in Erdheim-Chester Disease: CT and MR Imaging Findings. <i>Radiology</i> , 2010, 255, 586-594.	7.3	160
262	Phenotype-Haplotype Correlation of <i>IRF5</i> in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. <i>Journal of Rheumatology</i> , 2010, 37, 987-992.	2.0	54
263	Atypical dementia. <i>Lancet, The</i> , 2010, 376, 656.	13.7	1
264	ECLIPSE: a French Study Concerning the Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2010, 116, 5134-5134.	1.4	1
265	Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?. <i>Blood</i> , 2010, 116, 4716-4716.	1.4	0
266	IFN $\gamma$ kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 5294-5299.	7.1	205
267	Absence of <i>Mycobacterium tuberculosis</i> in Arterial Lesions from Patients with Takayasu's Arteritis. <i>Journal of Rheumatology</i> , 2009, 36, 1682-1685.	2.0	38
268	Pulmonary autoimmunity as a feature of autoimmune polyendocrine syndrome type 1 and identification of KCNKG as a bronchial autoantigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4396-4401.	7.1	98
269	Cardiac Involvement in Erdheim-Chester Disease. <i>Circulation</i> , 2009, 119, e597-8.	1.6	119
270	Letter by Guettrot-Imbert et al Regarding Article, "Early Diagnosis and Treatment of Atrioventricular Block in the Fetus Exposed to Maternal Anti-SSA/Ro-SSB/La Antibodies" author reply e168.	1.6	1



#	ARTICLE	IF	CITATIONS
271	Human lupus, fewer Treg cells indeed: Comment on the article by Venigalla et al. Arthritis and Rheumatism, 2009, 60, 630-630.	6.7	5
272	Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients. Arthritis and Rheumatism, 2009, 61, 577-582.	6.7	67
273	Is <sup>18</sup> F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in takayasu arteritis?. Arthritis and Rheumatism, 2009, 60, 1193-1200.	6.7	157
274	<sup>18</sup> F-fluorodeoxyglucose positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis and Rheumatism, 2009, 60, 3128-3138.	6.7	94
275	Rituximab may form a complex with iGm <sup>Î</sup> mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis and Rheumatism, 2009, 60, 3848-3855.	6.7	129
276	Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor. Immunity, 2009, 30, 899-911.	14.3	1,955
277	FoxP3+ Regulatory T Cells Suppress Early Stages of Granuloma Formation but Have Little Impact on Sarcoidosis Lesions. American Journal of Pathology, 2009, 174, 497-508.	3.8	116
278	Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: Comment on the article by Koneru et al. Arthritis and Rheumatism, 2008, 59, 153-153.	6.7	0
279	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. Clinical Pharmacokinetics, 2008, 47, 277-284.	3.5	48
280	Multidisciplinary approach of organic catatonia in children and adolescents may improve treatment decision making. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1393-1398.	4.8	54
281	Plasma Exchange in Patients with Stuporous Catatonia and Systemic Lupus Erythematosus. Psychotherapy and Psychosomatics, 2008, 77, 195-196.	8.8	31
282	Imatinib mesylate for platelet-derived growth factor receptor-beta positive Erdheim-Chester histiocytosis. Blood, 2008, 111, 5413-5415.	1.4	74
283	Prominent Plasmacytosis Following Intravenous Immunoglobulin Correlates with Clinical Improvement in Guillain-Barré Syndrome. PLoS ONE, 2008, 3, e2109.	2.5	17
284	Bilateral Adrenal Infiltration in Erdheim-Chester Disease. Report of Seven Cases and Literature Review. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2007-2012.	3.6	53
285	Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report. Cardiology, 2007, 107, 73-80.	1.4	103
286	Relationship between blood hydroxychloroquine and desethylchloroquine concentrations and cigarette smoking in treated patients with connective tissue diseases. Annals of the Rheumatic Diseases, 2007, 66, 1547-1548.	0.9	28
287	Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2007, 66, 821-824.	0.9	176
288	Hydroxychloroquine in systemic lupus erythematosus. Lancet, The, 2007, 369, 1257-1258.	13.7	31

#	ARTICLE	IF	CITATIONS
289	Potentialisation de l'association de fluindione et de warfarine par la dexaméthasone dans le myélome multiple et l'amylose AL. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 845-851.	0.0	0
290	Potentialisation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. <i>Joint Bone Spine</i> , 2007, 74, 446-452.	1.6	18
291	Characteristics and Long-Term Outcome of 15 Episodes of Systemic Lupus Erythematosus-Associated Hemophagocytic Syndrome. <i>Medicine (United States)</i> , 2006, 85, 169-182.	1.0	112
292	Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. <i>Arthritis and Rheumatism</i> , 2006, 54, 184-191.	6.7	130
293	Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 54, 3284-3290.	6.7	274
294	Variability in the efficacy of interferon- $\beta$ in Erdheim-Chester disease by patient and site of involvement: Results in eight patients. <i>Arthritis and Rheumatism</i> , 2006, 54, 3330-3336.	6.7	150
295	Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. <i>Brain</i> , 2006, 129, 986-995.	7.6	65
296	Bone Involvement in Erdheim-Chester Disease: Imaging Findings including Periostitis and Partial Epiphyseal Involvement. <i>Radiology</i> , 2006, 238, 632-639.	7.3	129
297	The immune paradox of sarcoidosis and regulatory T cells. <i>Journal of Experimental Medicine</i> , 2006, 203, 359-370.	8.5	392
298	High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. <i>Haematologica</i> , 2006, 91, 1121-5.	3.5	26
299	Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. <i>Autoimmunity Reviews</i> , 2005, 4, 111-115.	5.8	142
300	Corrected QT interval in anti-SSA-positive adults with connective tissue disease: Comment on the article by Lazzarini et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 676-677.	6.7	28
301	Association of the R92QTNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease. <i>Arthritis and Rheumatism</i> , 2005, 52, 608-611.	6.7	58
302	Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2005, 175, 8392-8400.	0.8	416
303	Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1279-1282.	2.5	88
304	Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. <i>Journal of Experimental Medicine</i> , 2005, 201, 1999-2010.	8.5	105
305	Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. <i>Arthritis Research</i> , 2005, 7, 69.	2.0	75
306	Cardiovascular Involvement, an Overlooked Feature of Erdheim-Chester Disease. <i>Medicine (United States)</i> , 2005, 84, 1000-1005.	1.0	229

#	ARTICLE	IF	CITATIONS
307	Ovarian vein thrombosis in the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2004, 50, 183-186.	6.7	37
308	Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. <i>Arthritis and Rheumatism</i> , 2004, 50, 1549-1560.	6.7	72
309	Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2004, 50, 3260-3264.	6.7	56
310	Outcome of pregnancies in patients with anti-SSA/Ro antibodies: A study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. <i>Arthritis and Rheumatism</i> , 2004, 50, 3187-3194.	6.7	156
311	Nucleosomes in the pathogenesis of systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 529-558.	1.9	69
312	Late-Onset Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2004, 83, 348-359.	1.0	204
313	Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty-three cases compared with a control group. <i>Arthritis and Rheumatism</i> , 2003, 48, 3207-3211.	6.7	295
314	Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. <i>Arthritis and Rheumatism</i> , 2003, 48, 3487-3496.	6.7	49
315	Anetoderma and its prothrombotic abnormalities. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 1008-1012.	1.2	56
316	Case Study: Effectiveness of Plasma Exchange in an Adolescent With Systemic Lupus Erythematosus and Catatonia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 497-499.	0.5	35
317	Recurrent Myocardial Infarction in a Patient With Paroxysmal Nocturnal Hemoglobinuria. <i>Circulation</i> , 2003, 108, e91-2.	1.6	1
318	Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. <i>Neurology</i> , 2002, 59, 1468-1469.	1.1	20
319	drug-induced hemophagocytosis. <i>American Journal of Medicine</i> , 2002, 112, 592-593.	1.5	57
320	Evidence of transplacental passage of hydroxychloroquine in humans. <i>Arthritis and Rheumatism</i> , 2002, 46, 1123-1124.	6.7	110
321	Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. <i>Journal of Rheumatology</i> , 2002, 29, 2571-6.	2.0	111
322	Epithelioid sarcoma mimicking abscess: review of the MRI appearances. <i>Skeletal Radiology</i> , 2001, 30, 173-177.	2.0	21
323	Lupus band test yields negative results in primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 488-489.	6.7	3
324	Calreticulin, a Potential Cell Surface Receptor Involved in Cell Penetration of Anti-DNA Antibodies. <i>Journal of Immunology</i> , 2001, 166, 6423-6429.	0.8	54

#	ARTICLE	IF	CITATIONS
325	The role of nucleosomes in lupus. <i>Current Opinion in Rheumatology</i> , 2000, 12, 369-373.	4.3	76
326	Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 43, 76-84.	6.7	237
327	Quantitative radioligand assays using de novo synthesized recombinant autoantigens in connective tissue diseases: New tools to approach the pathogenic significance of anti-RNP antibodies in rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2000, 43, 689.	6.7	67
328	Potential of Vitamin K Antagonists by High-Dose Intravenous Methylprednisolone. <i>Annals of Internal Medicine</i> , 2000, 132, 631.	3.9	49
329	Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. <i>Ocular Immunology and Inflammation</i> , 2000, 8, 293-301.	1.8	101
330	The role of B-mode ultrasonography and electron beam computed tomography in evaluation of Takayasu's arteritis: A study of 43 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 30, 25-32.	3.4	45
331	â€œCatastrophicâ€•Diagnosis of the Antiphospholipid Syndrome. <i>Annals of Internal Medicine</i> , 1999, 131, 798-799.	3.9	3
332	Massive ovarian haemorrhage complicating oral anticoagulation in the Antiphospholipid Syndrome: a report of three cases. <i>Lupus</i> , 1999, 8, 482-485.	1.6	23
333	Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. <i>Nature Genetics</i> , 1999, 22, 352-355.	21.4	1,375
334	The key role of nucleosomes in lupus. <i>Arthritis and Rheumatism</i> , 1999, 42, 833-843.	6.7	165
335	Systemic lupus erythematosus in patients native to West and Central Africa: Comment on the article by Bae et al. <i>Arthritis and Rheumatism</i> , 1999, 42, 1560-1561.	6.7	8
336	Early anti-nucleosome autoantibodies from a single MRL <sup>lpr/lpr</sup> mouse: fine specificity, V gene structure and pathogenicity. <i>European Journal of Immunology</i> , 1998, 28, 3411-3422.	2.9	22
337	Hyperthyroidism-associated chorea. <i>Lancet, The</i> , 1998, 352, 239.	13.7	4
338	Systemic Capillary Leak Syndrome. <i>American Journal of Medicine</i> , 1997, 103, 514-519.	1.5	146
339	Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus. Correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. <i>Arthritis and Rheumatism</i> , 1997, 40, 2217-2225.	6.7	165
340	Activated protein C and pulmonary embolism. <i>Lancet, The</i> , 1996, 347, 1841-1842.	13.7	1
341	Binding of nucleosomes to a cell surface receptor: Redistribution and endocytosis in the presence of lupus antibodies. <i>European Journal of Immunology</i> , 1996, 26, 472-486.	2.9	84
342	Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1995, 38, 1485-1491.	6.7	141

#	ARTICLE	IF	CITATIONS
343	Anti-Î²2-Glycoprotein I antibodies and thrombosis. <i>Clinical Reviews in Allergy and Immunology</i> , 1995, 13, 67-72.	6.5	7
344	Diabetes mellitus after abdominal radiation therapy. <i>Lancet, The</i> , 1995, 346, 633-634.	13.7	57
345	Nucleosome-restricted antibodies are detected before anti-dsdna and/or antihistone antibodies in serum of mrl-mp lpr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. <i>Arthritis and Rheumatism</i> , 1994, 37, 1684-1688.	6.7	192
346	Skeletal muscle lymphoma in patients with the acquired immunodeficiency syndrome: a diagnostic challenge. <i>Arthritis and Rheumatism</i> , 1993, 36, 426-427.	6.7	25
347	Association of anti-Î²2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1992, 93, 181-186.	1.5	264